the aid library

LIST OPTIONS

Filter

13784

Sort by:

Direction:

Download (280)

View PDF (375)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (238)

View PDF (220)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (100)

View PDF (118)

World Humanitarian Data and Trends 2018

OCHA Health Affairs (2018) C2

World Humanitarian Data and Trends presents global- and country-level data-and-trend analysis about humanitarian crises and assistance. Its purpose is to consolidate this information and present it in an accessible way, providing policymakers, researchers and humanitarian practitioners with an evid... more

Download (167)

View PDF (183)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 10 August 2023

World Health Organization WHO (2023) C_WHO

Download (239)

View PDF (181)

Considerations for developing a national genomic surveillance strategy or action plan for pathogens with pandemic and epidemic potential

World Health Organization WHO (2023) C_WHO

Pathogen genomic surveillance has become a priority for public health systems in recent years. Genomic sequencing is increasingly being used to characterize pathogens and monitor important public health priorities (e.g. poliovirus, influenza virus, Mycobacterium tuberculosis and Vibrio cholerae, ant... more

Download (281)

View PDF (240)

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended

World Health Organization WHO (2023) CC

Ebola disease and Marburg disease outbreaks continue to occur in Africa, with increased frequency. In addition to resulting in high mortality and morbidity, the outbreaks generate fear and mistrust about the response activities within the communities affected. Infection prevention and control (IP... more

Download (174)

View PDF (163)

WHO report on the global tobacco epidemic, 2023: protect people from tobacco smoke

World Health Organisation (WHO) (2023) C_WHO

The ninth WHO report on the global tobacco epidemic tracks the progress made by countries in tobacco control since 2008 and, marks 15 years since the introduction of the MPOWER technical package which is designed to help countries implement the demand-reduction measures of the WHO Framework Conventi... more

Download (249)

View PDF (361)

Policies to protect children from the harmful impact of food marketing: WHO guideline

World Health Organisation (WHO) (2023) C_WHO

Children continue to be exposed to powerful food marketing, which predominantly promotes foods high in saturated fatty acids, trans-fatty acids, free sugars and/or sodium and uses a wide variety of marketing strategies that are likely to appeal to children. Food marketing has a harmful impact on chi... more

Download (226)

View PDF (206)

Target product profiles for animal plasma-derived antivenoms: antivenoms for treatment of snakebite envenoming in sub-Saharan Africa

World Health Organisation (WHO) (2023) C_WHO

This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document: Broad spectrum Pan-African polyvalent antivenoms: products ... more

Download (181)

View PDF (166)

Water safety plan manual: step-by-step risk management for drinking-water suppliers, 2nd ed

World Health Organisation (WHO) (2023) C_WHO

Safe drinking-water management must consider drinking-water quality, acceptability and quantity in the context of public health protection. In this manual, the term “safety” encompasses these three elements. Although the principles in this manual can be broadly applied to all types of drinking-w... more

Download (207)

View PDF (179)

Supporting the routine use of evidence during the policy-making process: a WHO checklist

World Health Organisation (WHO) (2023) C_WHO

This checklist is for any organization or person supporting the routine use of evidence in the process of policy-making. Evidence-informed policy-making (EIPM) is essential for achieving the Sustainable Development Goals (SDGs) and universal health coverage (UHC). Its importance is emphasized in WH... more

Download (482)

View PDF (583)

Accelerating WHO FCTC Implementation in the WHO South-East Asia Region: A Practical Approach

World Health Organization (WHO), Regional Office for South-East-Asia (2017) C_WHO

The WHO Framework Convention on Tobacco Control (‎WHO FCTC)‎ is an evidence-based treaty that reaffirms the right of all people to the highest standard of health and was developed in response to the globalization of the tobacco epidemic. Member States of the WHO South-East Asia Region have made... more

Download (137)

View PDF (168)

Access to controlled medicines for pain management in the WHO South-East Asia Region

World Health Organisation (WHO) (2023) C_WHO

The availability of controlled medicines is crucial for patients requiring palliative care, pain relief and symptom management. Many individuals worldwide, especially in low- and middle-income countries, continue to experience limited access to these essential medicines. Enhancing access to controll... more

Download (183)

View PDF (113)

WHO Tanzania 2022 Annual Report

World Health Organisation (WHO) (2023) C_WHO

The Annual Report summarizes what has been achieved in the year 2022, how WHO supported the country priority, how WHO took the lead in health in bringing together partners to help the country achieve its strategic goals as a result be on track on its commitment on the SDG goals. The report also high... more

Download (261)

View PDF (261)

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Policy brief
recommended

World Health Organization WHO (2022) C_WHO

Cryptococcal disease, particularly cryptococcal meningitis is a significant cause of morbidity and mortality among people living with HIV with advanced HIV disease. It is estimated that it is responsible for nearly 19% of AIDS-related mortality, second only to tuberculosis. Rapid screening, diagnosi... more

Download (376)

View PDF (291)

Antibiotic Guidelines, 2019 (First edition) - Myanmar

World Health Organization WHO (2019) C_WHO

This is the first edition of Empiric Antibiotic Guidelines, as a guidance to all medical practitioners at North Okklapa General & Teaching Hospital. Antibiotics are critical in the management of infection and can have a significant impact in reducing morbidity and mortality. Emerging antimicrobia... more

Download (117)

View PDF (156)

De l’intention a l’action: perspectives régionales. Analyse des consultations régionales informelles avec des personnes vivant avec une maladie non transmissible ou un trouble de la santé mentale

World Health Organisation (WHO) (2023) C_WHO

Ce rapport inclut des analyses tirées des consultations régionales informelles menées dans la Région africaine, dans les Caraïbes et en Amérique du Nord, dans la Région européenne, dans la Région de la Méditerranée orientale, en Amérique latine ainsi que dans la Région de l’Asie du Su... more

Download (281)

View PDF (217)

Dementia in Latin America and the Caribbean: Prevalence, Incidence, Impact, and Trends over Time

World Health Organisation (WHO) (2023) C_WHO

The chapter Dementia in Latin America and the Caribbean: Prevalence, Incidence, Impact, and Trends over Time, is part of the publication series titled “Decade of Healthy Aging: situation and challenges”. This document aims to provide an outline of the current situation in Latin America and the C... more

Download (215)

View PDF (116)

Investir pour une meilleure santé pour tous : Appel à investissement – OMS Niger Stratégie de Coopération de l’OMS avec le Niger 2023-2027

World Health Organisation (WHO) (2023) C_WHO

L'OMS est un partenaire de confiance du Gouvernement du Niger depuis 1960. En tant que conseiller principal du gouvernement en matière de santé publique et présente dans toutes les régions du pays, l'OMS apporte un soutien technique et financier de qualité et bien coordonné dans le cadre des S... more

Download (124)

View PDF (157)

De l’intention a l’action : le pouvoir des individus. Perspectives de personnes avec une expérience vécue de maladie nontransmissible, de trouble de la santé mentale et de maladie neurologique

World Health Organisation (WHO) (2023) C_WHO

Il s’agit du premier rapport d’une collection de l’OMS intitulée De l’intention à l’action, qui vise à renforcer la base de données probantes sur l’impact de la participation significative et à combler le manque d’approches normalisées pour permettre la participation significativ... more

Infection prevention and control guideline for Ebola and Marburg disease, August 2023 recommended

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Policy brief recommended

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Policy brief
recommended